Patents by Inventor Hannah S. White

Hannah S. White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS
    Publication number: 20230241059
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with a Bruton's tyrosine kinase (BTK) inhibitor.
    Type: Application
    Filed: August 29, 2022
    Publication date: August 3, 2023
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
    Patent number: 11629150
    Abstract: This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Grant
    Filed: December 14, 2020
    Date of Patent: April 18, 2023
    Assignee: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
  • MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF
    Publication number: 20230043305
    Abstract: This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
    Type: Application
    Filed: February 28, 2022
    Publication date: February 9, 2023
    Applicant: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Patricia Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
  • Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors
    Patent number: 11446295
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with a Bruton's tyrosine kinase (BTK) inhibitor.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: September 20, 2022
    Assignee: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • Morphic forms of G1T38 and methods of manufacture thereof
    Patent number: 11261193
    Abstract: This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: March 1, 2022
    Assignee: GI Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Patricia Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
  • MORPHIC FORMS OF TRILACICLIB AND METHODS OF MANUFACTURE THEREOF
    Publication number: 20210387993
    Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1, 5]pyrrolo[2,3 -d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
    Type: Application
    Filed: April 21, 2021
    Publication date: December 16, 2021
    Applicant: G1 Therapeutics, Inc.
    Inventors: Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
  • SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES
    Publication number: 20210122755
    Abstract: This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Application
    Filed: December 14, 2020
    Publication date: April 29, 2021
    Applicant: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
  • Morphic forms of trilaciclib and methods of manufacture thereof
    Patent number: 10988479
    Abstract: An advantageous isolated morphic form of trilaciclib which is 2?-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: April 27, 2021
    Assignee: G1 Therapeutics, Inc.
    Inventors: Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
  • Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
    Patent number: 10865210
    Abstract: This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 15, 2020
    Assignee: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
  • MORPHIC FORMS OF G1T38 AND METHODS OF MANUFACTURE THEREOF
    Publication number: 20200123168
    Abstract: This invention provides an unexpectedly stable, highly crystalline form of the di-HCl salt of 2?-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7?,8?-dihydro-6?H-spiro[cyclohexane-1,9?-pyrazino[1?,2?:1,5]pyrrolo[2,3-d]pyrimidin]-6?-one for advantageous therapeutic pharmaceutical efficacy and dosage form stability.
    Type: Application
    Filed: December 19, 2019
    Publication date: April 23, 2020
    Applicant: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, Patrica Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
  • ANTI-NEOPLASTIC COMBINATIONS AND DOSING REGIMENS USING CDK4/6 INHIBITOR COMPOUNDS TO TREAT RB-POSITIVE TUMORS
    Publication number: 20190151311
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with a Bruton's tyrosine kinase (BTK) inhibitor.
    Type: Application
    Filed: January 22, 2019
    Publication date: May 23, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • SYNTHESIS OF N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES
    Publication number: 20190135820
    Abstract: This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Alexander Smith, Hannah S. White, francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
  • Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat RB-positive tumors
    Patent number: 10231969
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: March 19, 2019
    Assignee: GI Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • TREATMENT OF RB-NEGATIVE TUMORS USING TOPOISOMERASE INHIBITORS IN COMBINATION WITH CYCLIN DEPENDENT KINASE 4/6 INHIBITORS
    Publication number: 20190030034
    Abstract: This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors. In one aspect, the improved treatment of select Rb-negative cancers is disclosed using specific compounds disclosed herein in combination with a topoisomerase I inhibitor.
    Type: Application
    Filed: September 26, 2018
    Publication date: January 31, 2019
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
  • Anti-Neoplastic Combinations and Dosing Regimens using CDK4/6 Inhibitor Compounds to Treat RB-Positive Tumors
    Publication number: 20170182043
    Abstract: This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes. In one aspect, treatments of select RB-positive cancers are disclosed using specific CDK4/6 inhibitors in combination or alternation with another chemotherapeutic, for example, an additional kinase inhibitor, PD-1 inhibitor, or BCL-2 inhibitor, or combination thereof.
    Type: Application
    Filed: March 13, 2017
    Publication date: June 29, 2017
    Applicant: G1 Therapeutics, Inc.
    Inventors: Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White